Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Cancer Type/Condition:  Brain tumor, adult: Oligodendroglioma/Oligodendroglial tumors
Country:  U.S.A.
Trial Type:  Treatment
Trial Status:  Active
Results 1-25 of 62 for your search:
Start Over
Light Sedation or Intubated General Anesthesia in Patients With Brain Cancer Undergoing Craniotomy
Phase: Phase IV
Type: Supportive care, Treatment
Status: Active
Age: 19 and over
Sponsor: Other
Protocol IDs: OSU-12161, NCI-2014-01110, NCT02193568
Radiation Therapy With or Without Temozolomide in Treating Patients With Anaplastic Glioma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000582632, EORTC-26053, CAN-NCIC-CEC1, RTOG-0834, EORTC-22054, EUDRACT-2006-001533-17, SPRI-EORTC-26053, MERCK-EORTC-26053, MRC-BR14, COGNO-EORTC-26053, CEC1, NCT00626990
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000654697, ECOG-E3F05, E3F05, NCT00978458
Fluorescence-guided Surgery for Low- and High-grade Gliomas
Phase: Phase III
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: IRB#10BN132, NCT01502280
Combination Chemotherapy With BBBD Followed By Sodium Thiosulfate in Treating Patients With Anaplastic Oligodendroglioma or Oligoastrocytoma
Phase: Phase II, Phase I
Type: Supportive care, Treatment
Status: Active
Age: 18 to 75
Sponsor: NCI, Other
Protocol IDs: OHSU-2868, P30CA069533, 8507, SOL-04058-L, 2868, OHSU-8507, OHSU-SOL-04058-L, NCT00303849
Radiosurgery for Glioblastoma
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Over 65
Sponsor: Other
Protocol IDs: 2006P-000464, NCT00456612
Intrathecal Trastuzumab for Leptomeningeal Metastases in HER2+ Breast Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: NU 10C03, STU00040150, NCT01325207
Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: BTTC09-01, NCI-2011-03056, NCT01434602
Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-01989, CDR0000737109, NCCTG-N1174, N1174, U10CA180821, U10CA025224, NCT01648348
Phase I/II Trial of Safety and Anti-tumor Efficacy of AXL1717(Picropodophyllin) in the Treatment of Recurrent Malignant Astrocytomas
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 11090804, VABC; GCR, NCT01721577
Intra-operative Use of Indigo Carmine Dye for the Delineation of Ill Defined Tumor Borders Using Stereotactic Injection
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: 1106011772, NCT01767415
A Phase I/II Study of High-dose L-methylfolate in Combination With Temozolomide and Bevacizumab in Recurrent High Grade Glioma
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: VICC NEU 1308, NCT01891747
Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 75
Sponsor: NCI, Other
Protocol IDs: BRN0023, NCI-2013-02012, P30CA124435, NCT01977677
Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Pharmaceutical / Industry
Protocol IDs: NLG2102, NCT02052648
Study of Orally Administered AG-221 in Subjects With Advanced Solid Tumors, Including Glioma, and With Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: AG221-C-003, NCT02273739
PLX3397 in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN)
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 3 to 30
Sponsor: NCI
Protocol IDs: 150093, 15-C-0093, NCT02390752
Treating Patients With High-Grade Glioma With Intra-Arterial (IA) Carboplatin-based Chemotherapy, With or Without Sodium Thiosulfate
Phase: Phase II
Type: Supportive care, Treatment
Status: Active
Age: 18 to 75
Sponsor: NCI, Other
Protocol IDs: OHSU-922, ONC-02059-L, 922, 7328, OHSU-7328, OHSU-ONC-02059-L, CASE-CCF-6385, NCT00075387
Temozolomide in Treating Patients With Low-Grade Glioma
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000448883, 99102, BTRC-9902, H7858-16278-07, UCSF-99102, UCSF-H7858-16278-07, NCT00313729
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Any age
Sponsor: Other
Protocol IDs: 05-122, MSKCC-05122, NCT00445965
Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 6803, NCI-2010-00714, P30CA015704, UWCC-6803, FHCRC-6803, IR-6803, NCCN-C01, NCT00823797
Everolimus in Treating Patients With Recurrent or Progressive Low-Grade Glioma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000632931, UCSF-H7858-32860-01, 08109, CRAD001CUS58T, H7858-32860-01, NCT00831324
Safety Study of Aminolevulinic Acid (ALA) to Improve Visibility of Brain Tumors During Surgery
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 104974, NCT00961090
Antineoplaston Therapy in Treating Patients With Brain Tumors
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000066489, BC-BT-9, NCT00003457
Antineoplaston Therapy in Treating Patients With Primary Malignant Brain Tumors
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000066512, BC-BT-21, NCT00003475
Safety Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Tumors of the Brain
Phase: Phase II
Type: Diagnostic, Treatment
Status: Active
Age: 18 to 72
Sponsor: Other
Protocol IDs: 10101, NCT01116661
Start Over